The Real Mini-Gastric Bypass

18/11/2024

MGB and Risk of Blindness in Thin Diabetics

Analyzing the Predicted Decreased Risk of Blindness: Mini-Gastric Bypass (Billroth II) Treatment of “Thin” Diabetics

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia.

A major complication of diabetes is diabetic retinopathy, which can lead to vision loss and blindness.

While traditional medical therapies focus on glycemic control they often fall short as the rising rate diabetic eye disease skyrockets.

The long experience with the Billroth II and its effectiveness in the improvement or resolution of diabetes led us to consider the Mini-Gastric Bypass (MGB) as a treatment strategy in Thin diabetics.

This study evaluated the impact of MGB surgery on the risk of blindness in a cohort of "thin" diabetic patients.

By analyzing pre-operative and post-operative HbA1c levels and calculating the estimated risk of blindness, we found a significant reduction in the probable risk of blindness post-operatively.

The observed reduction in HbA1c levels and the associated decrease in the estimated risk of blindness suggest that MGB surgery may be a valuable tool in the management of diabetes and the prevention of diabetic retinopathy.

Conclusion
The findings of this study provide strong evidence for the efficacy of MGB surgery in reducing the risk of blindness in diabetic patients.

The significant reduction in HbA1c levels and the associated decrease in the estimated risk of blindness highlight the potential of MGB surgery as a valuable therapeutic option for managing diabetes and its complications.

However, further long-term studies are needed to fully understand the long-term benefits and potential risks of this surgical intervention.

18/11/2024

Early Surgical Intervention for Rx Diabetes:
A Game-Changer for “Thin” Diabetics:
70% of Patients had a Low Normal HbA1c of Less than 7!!

Diabetes mellitus, often associated with obesity, is a complex metabolic disorder.

This study evaluated the impact of modified Mini-Gastric Bypass (MGB) surgery on glycemic control in a cohort of “thin” diabetic patients.

A prospective cohort study was conducted to analyze pre-operative and post-operative HbA1c levels, C-peptide levels, and vitamin B12 levels.

Notably there was no correlation between pre-operative BMI and HbA1c levels.

The modified MGB surgery resulted in significant improvements in glycemic control, with 20% of patients achieving sustained HbA1c levels below 7.0% for 7 years.

Additionally, 10% of patients achieved HbA1c levels between 7.0 and 7.5%, still representing substantial improvement.

The remaining 3 patients still experienced HbA1c level

18/11/2024

"Early surgical intervention, tailored to the specific needs of individual patients, may be a valuable strategy for improving glycemic control and preventing diabetes-related complications."

Our newest research data:
Modified version of the MGB can result in excellent improvement of "thin" diabetics

Early Surgical Intervention: A Safe and Effective Approach for “Thin” Diabetes

Diabetes mellitus, often associated with obesity, is a complex metabolic disorder. This study evaluated the impact of a tailored Mini-Gastric Bypass (MGB) procedure on glycemic control in a cohort of “thin” diabetic patients.

A cohort study was conducted to analyze pre-operative and post-operative HbA1c levels, C-peptide levels, and vitamin B12 levels.

Contrary to the conventional understanding, a significant correlation between pre-operative BMI and HbA1c levels was not observed.

MGB surgery resulted in significant improvements in glycemic control, with 70% of patients achieving HbA1c levels below 7.0% at the 7-year follow-up.

This level of long-term glycemic control is remarkable and suggests that early surgical intervention can be a transformative approach for “thin” diabetic patients.

Importantly, the surgery was well-tolerated, with minimal weight loss (mean weight loss of only 3.5 kg) and no significant nutritional deficiencies.

These findings challenge the traditional paradigm of diabetes as primarily an obesity-related disorder.

Early surgical intervention, tailored to the specific needs of individual patients, may be a valuable strategy for improving glycemic control and preventing diabetes-related complications.

Further research is needed to explore the underlying mechanisms and optimize patient selection criteria for this promising approach.

18/11/2024

Stop diabetes now!

The Saturated Fat Dilemma: A Potential Surgical Solution
The Problem:

Despite widespread awareness of the detrimental health effects of saturated fat, consumption remains high in many Western diets. While dietary recommendations emphasize reducing saturated fat intake, many individuals struggle to adhere to these guidelines. This is particularly concerning given the strong link between saturated fat and chronic diseases like heart disease, stroke, and certain cancers.

A Novel Approach: The Billroth II Procedure
The Billroth II procedure, a surgical intervention historically used for various gastrointestinal conditions, offers a potential solution to the challenges of managing saturated fat intake. This procedure involves bypassing a significant portion of the small intestine, including the duodenum, where a significant portion of fat digestion and absorption occurs.

By bypassing this critical area, the body's ability to digest and absorb dietary fat, particularly saturated fat, is significantly reduced. This can lead to a more restrictive diet, naturally limiting the intake of harmful fats and promoting a healthier dietary pattern.

Conclusion:
While dietary modifications and lifestyle changes remain the cornerstone of preventing chronic diseases, the Billroth II procedure presents an intriguing option for individuals who struggle to adhere to low-fat diets or who have a significant risk of saturated fat-related health problems. It's essential to weigh the potential benefits and risks of such a surgical intervention with a healthcare provider. Further research is needed to fully understand the long-term implications of this procedure and its impact on overall health.

Mgb billroth II Hx - Download as a PDF or view online for free

17/11/2024

Diabetes; No More!

Our data, Imagine a series of 55 severe diabetics treated 7 years ago and most were on insulin and now the majority are off insulin!
It's a hundred years old surgery, the Billroth II!

Below shows before surgery 84% needed insulin and 6 years later only 8% needed insulin.

29/10/2024

Dr Kular, Dr Manchanda & Dr Rutledge are Happy to announce preliminary data of complete reversal of diabetes in thin diabetics for more than 6 years.

To repeat Kular Manchanda and Rutledge are happy to announce research demonstrating that severe diabetes can be reversed or improved for more than 6 years with a brief mini gastric bypass surgery.

We can reverse or improve diabetes for over 6 years with a brief 30 to 60 minute surgery The mini gastric bypass.

Follow Dr. Rutledge on Facebook ://www.facebook.com/DrRutledge/or Join one of our online groups:https://www.facebook.com/groups/MiniGastricB...

17/10/2024

Imagine! 30 minutes to long term Reversal of Diabetes, Severe Diabetes.
Now We Have it! “Kular & Manchanda:”
55 “Thin Diabetics” Rx MGB, => 7 Years Follow Up

16/10/2024

What if Diabetes could be:
Reversed for 6++ years or More? with a Simple,
30 min. Procedure? (the MGB2)

Follow Dr. Rutledge on Facebook ://www.facebook.com/DrRutledge/or Join one of our online groups:https://www.facebook.com/groups/MiniGastricB...

16/10/2024

Kular, Manchanda & Rutledge
First Report Successful Long Term, Surgical Rx “Thin” Diabetics
(52 pts, 7 yr Follow Up), Mean HbA1c Pre: 12.6, Post: 6.1

15/10/2024

What if Diabetes Could Be Reversed (Cured??) Preliminary Data...
From studies from Dr Kular, Dr Manchanda & DrR Rutledge

Follow Dr. Rutledge on Facebook ://www.facebook.com/DrRutledge/or Join one of our online groups:https://www.facebook.com/groups/MiniGastricB...

15/10/2024

What if Diabetes Could Be Reversed (Cured??) Preliminary Data...
From studies from Dr Kular, Dr Manchanda & DDrR Rutledge

Share your videos with friends, family, and the world.

24/09/2024

MGB/OAGB successfully adopted nationwide in the United Kingdom with results equal to or above that of other forms of weight loss surgery in more seriously ill patients

🙂 See! That's what I told everyone 20 years ago.

Nationwide introduction of one-anastomosis gastric bypass (the MGB) in the UK
Int J Surg. 2024.

Abstract
Aim: This study assessed the impact of introducing one-anastomosis gastric bypass (OAGB/MGB) in the routine bariatric surgical practice in the UK.

Results:
59,226 patients underwent surgery

RYGB, 38,434;
SG, 24,702;
AGB, 12,627;
OAGB, 3,408;

30-day postop morbidity
Lower for OAGB 1.8%
RYGB 4.2%
SG 3.4%
Overall, at 12-mo > 25% TBWL
RYGB: 82.9%
SG: 65.4%
AGB: 23.9%
OAGB: 82.9%

OAGB highest 12-month total body weight loss

Conclusion: OAGB now safely implemented throughout the nation of the United KingdomUK.
MGB/OAGB It has lower COMPLICATIONS and EXCELLENT weight loss, despite being offered to patients with more severe and complex obesity

National introduction of one-anastomosis (MGB) gastric bypass in the UK National Bariatric Surgery Registry
Andrew C Currie et al. Int J Surg. 2024.